Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects

David J. Hinton, Marely Santiago Vázquez, Jennifer R. Geske, Mario J. Hitschfeld, Ada M.C. Ho, Victor M Karpyak, Joanna M Biernacka, Doo Sup Choi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.

Original languageEnglish (US)
Article number2496
JournalScientific Reports
Volume7
Issue number1
DOIs
StatePublished - Dec 1 2017

Fingerprint

Metabolomics
Biomarkers
Alcohols
Alcohol Drinking
Therapeutics
Precision Medicine
Patient Rights
Pharmaceutical Preparations
Sample Size
acamprosate
Sensitivity and Specificity
Serum

ASJC Scopus subject areas

  • General

Cite this

Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. / Hinton, David J.; Vázquez, Marely Santiago; Geske, Jennifer R.; Hitschfeld, Mario J.; Ho, Ada M.C.; Karpyak, Victor M; Biernacka, Joanna M; Choi, Doo Sup.

In: Scientific Reports, Vol. 7, No. 1, 2496, 01.12.2017.

Research output: Contribution to journalArticle

Hinton, David J. ; Vázquez, Marely Santiago ; Geske, Jennifer R. ; Hitschfeld, Mario J. ; Ho, Ada M.C. ; Karpyak, Victor M ; Biernacka, Joanna M ; Choi, Doo Sup. / Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{c562b806c0da422c9d3bec55cc22165b,
title = "Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects",
abstract = "Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.",
author = "Hinton, {David J.} and V{\'a}zquez, {Marely Santiago} and Geske, {Jennifer R.} and Hitschfeld, {Mario J.} and Ho, {Ada M.C.} and Karpyak, {Victor M} and Biernacka, {Joanna M} and Choi, {Doo Sup}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02442-4",
language = "English (US)",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects

AU - Hinton, David J.

AU - Vázquez, Marely Santiago

AU - Geske, Jennifer R.

AU - Hitschfeld, Mario J.

AU - Ho, Ada M.C.

AU - Karpyak, Victor M

AU - Biernacka, Joanna M

AU - Choi, Doo Sup

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.

AB - Precision medicine for alcohol use disorder (AUD) allows optimal treatment of the right patient with the right drug at the right time. Here, we generated multivariable models incorporating clinical information and serum metabolite levels to predict acamprosate treatment response. The sample of 120 patients was randomly split into a training set (n = 80) and test set (n = 40) five independent times. Treatment response was defined as complete abstinence (no alcohol consumption during 3 months of acamprosate treatment) while nonresponse was defined as any alcohol consumption during this period. In each of the five training sets, we built a predictive model using a least absolute shrinkage and section operator (LASSO) penalized selection method and then evaluated the predictive performance of each model in the corresponding test set. The models predicted acamprosate treatment response with a mean sensitivity and specificity in the test sets of 0.83 and 0.31, respectively, suggesting our model performed well at predicting responders, but not non-responders (i.e. many non-responders were predicted to respond). Studies with larger sample sizes and additional biomarkers will expand the clinical utility of predictive algorithms for pharmaceutical response in AUD.

UR - http://www.scopus.com/inward/record.url?scp=85020054419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020054419&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02442-4

DO - 10.1038/s41598-017-02442-4

M3 - Article

C2 - 28566752

AN - SCOPUS:85020054419

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2496

ER -